A Phase 1/1B Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination with Irinotecan in Subjects with Advanced Solid Tumors.

Trial Profile

A Phase 1/1B Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination with Irinotecan in Subjects with Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2012

At a glance

  • Drugs Iniparib; Irinotecan
  • Indications Advanced breast cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Jun 2012 Additional trial identifier (20060101) identified as reported by ClinicalTrials.gov record.
    • 14 May 2012 Actual patient number is 59 according to ClinicalTrials.gov.
    • 26 May 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top